Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
Aspyron Inc is development stage company that will be completing preparations for ...
Aspyron Inc is development stage company that w...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of h...
Bio-Techne Corporation (NASDAQ: TECH) is a lead...
Repligen Corporation is a global bioprocessing company that develops and commercia...
Repligen Corporation is a global bioprocessing ...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
Join the National Investor Network and get the latest information with your interests in mind.